Daiichi Sankyo to commercialize mRNA COVID-19 vaccine in Japan within 2022 - BioSpectrum Asia

Retrieved on: 2021-10-26 05:52:43

Tags for this article:

Click the tags to see associated articles and topics

Daiichi Sankyo to commercialize mRNA COVID-19 vaccine in Japan within 2022 - BioSpectrum Asia. View article details on hiswai:

Excerpt

Daiichi Sankyo has announced the progress of development of DS-5670, an mRNA vaccine in Japan, being evaluated against the novel coronavirus ...

Article found on: www.biospectrumasia.com